CRLBFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Cresco Labs Inc.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 6, 2026

$0.58−0.02 (-3.13%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Cresco Labs Inc. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	656	724	771	843	822	476	129
Cost of Revenue	331	360	409	436	415	270	83
Gross Profit	325	364	362	407	406	207	46
Selling, General & Admin	247	255	299	351	318	229	94
Advertising Expenses	6.30	7.10	7.40	8.10	12	19	13
Operating Expenses	353	257	450	491	624	230	98
Operating Income	-28	107	-88	-84	-217	-23	-34
Interest Expense	42	38	44	58	51	31	7.88
Interest & Investment Income	3.75	2.92	2.15	–	–	–	–
Other Non-Operating Income	-67	-118	-59	–	–	–	–
Asset Impairment Charges	105	2.32	151	–	–	–	–
Gain (Loss) on Investments	–	-0.07	-0.50	–	–	–	–
Gain (Loss) on Sale of Assets	-2.37	-0.68	0.76	–	–	–	–
Legal Settlements	–	0.27	0	–	–	–	–
Pretax Income	-95	-11	-147	-127	-257	-64	-51
Income Tax Expense	45	50	33	89	40	29	14
Net Income incl. Noncontrolling Interests	-140	-60	-180	-216	-297	-93	-65
Minority Interest in Earnings	-4.64	14	-4.33	-3.80	23	9.39	-22
Net Income	-135	-74	-176	-212	-320	-102	-43
Net Income to Common	–	–	–	–	–	-82	-43
EPS (Basic)(per share)	-0.38	-0.22	-0.54	-0.71	-1.22	-0.39	-0.37
EPS (Diluted)(per share)	-0.38	-0.22	-0.54	-0.71	-1.22	-0.39	-0.37
Shares Outstanding (Basic, Weighted)(shares)	355	345	324	298	262	0.21	0.12
Shares Outstanding (Diluted, Weighted)(shares)	355	345	324	298	262	0.21	0.12
EBITDA	21	166	-25	-32	-179	8.33	-22
Provision for Credit Losses	0.17	0.33	0.31	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 49.5%
Operating margin: -4.3%
Net margin: -20.6%
Return on equity, FY2025: -33.2%

Financial strength

Current ratio: 2.59
Debt to equity: 1.27
Debt to assets: 36.0%
Cash to current liabilities: 57.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –